514 results on '"Wei, Shu-Chen"'
Search Results
2. Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies
3. A simplified fecal leukocyte esterase strip test results as a low cost, widely available, alternative bowel inflammation biomarker
4. Exacerbated gastrointestinal symptoms and long COVID in IBD patients with SARS-CoV-2 infection: A multi-center study from taiwan
5. Comparison of the magnetic resonance scoring systems for Crohn’s disease activity: MaRIA, simplified MaRIA, and Nancy scores
6. Development of the global inflammatory bowel disease visualization of epidemiology studies in the 21st century (GIVES-21)
7. Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial
8. Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study
9. Impact of the COVID-19 pandemic on inflammatory bowel disease care in Taiwan: A multicenter study
10. Global Hospitalization Trends for Crohn’s Disease and Ulcerative Colitis in the 21st Century: A Systematic Review With Temporal Analyses
11. Anemia in inflammatory bowel disease course is associated with patients' worse outcome
12. Evaluation of Persistent Efficacy of Diabetes Remission and Decline of Cardiovascular Risk After Laparoscopic Sleeve Gastrectomy: a Preliminary 1-Year Study
13. Dietary beliefs and information resources of ulcerative colitis patients in clinical remission: A cross-sectional survey in Taiwan
14. Invasive Pathobionts Contribute to Colon Cancer Initiation by Counterbalancing Epithelial Antimicrobial Responses
15. Characteristics of primary signet ring cell carcinoma of colon and rectum: a case control study
16. Effect of smoking on the development and outcomes of inflammatory bowel disease in Taiwan: a hospital-based cohort study
17. Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies
18. Nanotechnology for Targeted Inflammatory Bowel Disease Therapy: Challenges and Opportunities.
19. Inflammatory bowel disease and its treatment in 2018: Global and Taiwanese status updates
20. Microbiota and gastrointestinal cancer
21. Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial
22. MODELING THE TRANSITION TO THE FOURTH EPIDEMIOLOGIC STAGE OF INFLAMMATORY BOWEL DISEASE: PREVALENCE EQUILIBRIUM
23. The Global Evolution of Inflammatory Bowel Disease across Four Epidemiologic Stages
24. Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study
25. Ulcerative colitis
26. Vaccination in patients with inflammatory bowel disease–Asian perspectives: the results of a multinational web-based survey in the 8th Asian Organization for Crohn’s and Colitis meeting
27. Epidemiology, Disease Course, and Clinical Outcomes of Perianal Fistulas and Fissures Crohn’s Disease: A Nationwide Population-Based Study in Taiwan
28. Epithelial Notch signaling regulates lung alveolar morphogenesis and airway epithelial integrity
29. Trends and risk factors of mortality analysis in patients with inflammatory bowel disease: a Taiwanese nationwide population-based study
30. Response to letter to the editor “Anemia in inflammatory bowel disease course is associated with patients' worse outcome”
31. High-dose Dual Therapy Is Superior to Standard First-line or Rescue Therapy for Helicobacter pylori Infection
32. Additional file 1 of Development of the global inflammatory bowel disease visualization of epidemiology studies in the 21st century (GIVES-21)
33. Real-World Evidence of Effectiveness and Safety of Vedolizumab for Inflammatory Bowel Disease in Taiwan: A Prospective Nationwide Registry (VIOLET) Study
34. The pregnancy outcome and drug usage during pregnancy among Taiwanese inflammatory bowel disease patients
35. Patients with Inflammatory Bowel Disease have Higher Sonographic Enthesitis Scores than Normal Individuals: Pilot Study in Taiwan
36. Increase diagnostic accuracy in differentiating focal type autoimmune pancreatitis from pancreatic cancer with combined serum IgG4 and CA19-9 levels
37. Incidence and Risk Factor Analysis of Thromboembolic Events in East Asian Patients With Inflammatory Bowel Disease, a Multinational Collaborative Study
38. PET/MRI for evaluating subclinical inflammation of ulcerative colitis
39. The pregnancy outcome and drug usage during pregnancy among Taiwanese inflammatory bowel disease patients
40. Anemia in inflammatory bowel disease course is associated with patients' worse outcome
41. Perioperative optimization of Crohn's disease
42. Asian Organization for Crohnʼs and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti‐tumor necrosis factor treatment. Part 2: Management
43. Asian Organization for Crohnʼs and Colitis and Asian Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti‐tumor necrosis factor treatment. Part 1: Risk assessment
44. SHANK3 Regulates Intestinal Barrier Function Through Modulating ZO-1 Expression Through the PKCε-dependent Pathway
45. Evolutionarily conserved protein ERH controls CENP-E mRNA splicing and is required for the survival of KRAS mutant cancer cells
46. Global Hospitalization Trends for Crohn’s Disease and Ulcerative Colitis in the 21st Century: A Systematic Review With Temporal Analyses
47. A hospital-based study of clinical and genetic features of Crohn’s disease
48. Clinical Course of Hepatitis B Viral Infection in Patients Undergoing Anti-Tumor Necrosis Factor α Therapy for Inflammatory Bowel Disease
49. EP1308: 6-THIOGUANINE NUCLEOTIDE LEVELS AND ANTI-TNFα TROUGH LEVELS IN INFLAMMATORY BOWEL DISEASE PATIENTS ON COMBINATION THERAPY: A RETROSPECTIVE MULTICENTRE STUDY
50. EP1335: TRANSEPITHELIAL BARRIER DYSFUNCTION PROMOTES MICROBIOTA DYSBIOSIS HARBORING INVASIVE PATHOBIONTS TO INSTIGATE EPITHELIAL CLOCK-DRIVEN INFLAMMATION
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.